Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
Sinner F, Pinter M, Scheiner B, Ettrich TJ, Sturm N, Gonzalez-Carmona MA, Waidmann O, Finkelmeier F, Himmelsbach V, De Toni EN, Ben Khaled N, Mohr R, Fründt TW, Kütting F, Bömmel FV, Lieb S, Krug S, Bettinger D, Schultheiß M, Jochheim LS, Best J, Müller C, Keitel V, Venerito M. Sinner F, et al. Cancers (Basel). 2022 Dec 2;14(23):5966. doi: 10.3390/cancers14235966. Cancers (Basel). 2022. PMID: 36497447 Free PMC article.
First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis.
Möhring C, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Front Oncol. 2021 Nov 10;11:717397. doi: 10.3389/fonc.2021.717397. eCollection 2021. Front Oncol. 2021. PMID: 34858809 Free PMC article.
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.
Gonzalez-Carmona MA, Möhring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, Bolch M, Vogt A, Kaczmarek DJ, Heling DJ, Dold L, Nattermann J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Mohr RU, Weismüller TJ. Gonzalez-Carmona MA, et al. Sci Rep. 2022 Jan 19;12(1):1011. doi: 10.1038/s41598-021-04297-2. Sci Rep. 2022. PMID: 35046437 Free PMC article.
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study.
Welland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona MA, Kandulski A, Jeliazkova P, Best J, Fründt TW, Djanani A, Pangerl M, Maieron A, Greil R, Fricke C, Sookthai D, Günther R, Schmiderer A, Wege H, Venerito M, Ehmer U, Müller M, Strassburg CP, Weinmann A, Siebler J, Waidmann O, Lange CM, Saborowski A, Vogel A. Welland S, et al. Liver Cancer. 2022 Jan 14;11(3):219-232. doi: 10.1159/000521746. eCollection 2022 Jun. Liver Cancer. 2022. PMID: 35949288 Free PMC article.
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L, Berres ML, Gonzalez-Carmona M, Modest DP, Mohr R, Wree A, Venerito M, Strassburg C, Keitel V, Trautwein C, Luedde T, Roderburg C. Kehmann L, et al. BMC Cancer. 2023 May 22;23(1):470. doi: 10.1186/s12885-023-10972-6. BMC Cancer. 2023. PMID: 37217885 Free PMC article.
First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison.
Mahn R, Glüer OA, Sadeghlar F, Möhring C, Zhou T, Anhalt T, Monin MB, Kania A, Glowka TR, Feldmann G, Brossart P, Kalff JC, Schmidt-Wolf IGH, Strassburg CP, Gonzalez-Carmona MA. Mahn R, et al. Among authors: gonzalez carmona ma. J Hepatocell Carcinoma. 2024 Jan 13;11:81-94. doi: 10.2147/JHC.S432948. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38239279 Free PMC article.
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F, Vogt A, Mohr RU, Mahn R, van Beekum K, Kornek M, Weismüller TJ, Branchi V, Matthaei H, Toma M, Schmidt-Wolf IGH, Kalff JC, Strassburg CP, González-Carmona MA. Sadeghlar F, et al. Cancer Immunol Immunother. 2021 May;70(5):1451-1464. doi: 10.1007/s00262-020-02746-x. Epub 2020 Nov 12. Cancer Immunol Immunother. 2021. PMID: 33180184 Free PMC article.
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Möhring C, Frontado Graffe FJ, Bartels A, Sadeghlar F, Zhou T, Mahn R, Marinova M, Feldmann G, Brossart P, Glowka TR, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. J Gastrointest Oncol. 2023 Feb 28;14(1):352-365. doi: 10.21037/jgo-22-632. Epub 2023 Feb 15. J Gastrointest Oncol. 2023. PMID: 36915455 Free PMC article.
77 results